Moreover, we further clarified the decreased expression of CRTH2 in DLBCL cell lines (n = 7) in comparison with CD19+ B cells from PBMCs of healthy donors (n = 3) (Fig. 1G), among them LY1 cells (GCB subtype) and LY3 cells (non-GCB subtype) were chosen for subsequent experiments according to CRTH2 expression level. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.